Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 37, Issue 9, Pages 1268-1273Publisher
WILEY
DOI: 10.1002/hed.23743
Keywords
head and neck cancer; oral cancer; nasopharyngeal carcinoma; diabetes; metformin
Categories
Funding
- Taipei Medical University-Chi Mei Medical Center
Ask authors/readers for more resources
BackgroundThe purpose of this study was to examine the effect of metformin on head and neck cancer in patients with diabetes. MethodsWe compared 66,600 patients, all with diabetes and all newly diagnosed with head and neck cancer in 2002. Half were being treated with metformin for diabetes (Met(+)) and half were not (Met(-): controls). All were matched for comorbidities (obesity, coronary artery disease, hyperlipidemia, and hypertension), sex, and age. The risk of head and neck cancer at the end of 2011 was determined. ResultsThe incidence of head and neck cancer was 34% lower in the Met(+) cohort than in the Met(-) cohort (adjusted hazard ratio [HR]=0.66; 95% confidence interval [CI]=0.55-0.79). The risks for oropharyngeal cancer (adjusted HR=0.66; 95% CI=0.17-0.74) and nasopharyngeal carcinoma (NPC; adjusted HR=0.50; 95% CI=0.31-0.80) were significantly lower in the Met(+) cohort than in the Met(-) cohort. ConclusionMetformin is associated with a lower risk of developing head and neck cancer in patients with diabetes. (c) 2014 Wiley Periodicals, Inc. Head Neck 37: 1268-1273, 2015
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available